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ABSTRACT

A major paradigm shift in mental health has led to the ascendance of the view that
chronic psychopathology results from perturbed neural development. While most work
in this area examines schizophrenia, the current report extends the paradigm to bipolar
disorder (BD) in youth, thus demonstrating traction (not sure I understand what you mean
here) in the developmental-psychobiology perspective. To study the role of amygdala
dysfunction, we examined the neural mechanisms mediating face processing in 22 youth
(mean age 14.21 + 3.11 years) with BD and 21 controls of comparable age, gender, and
IQ. Event-related fMRI compared neural activation when attention was directed to
emotional aspects of faces (hostility, subjects’ own fearfulness) vs. non-emotional aspects
(nose width). Compared to controls, patients perceived greater hostility in neutral faces,
and reported more fear when viewing them. Also, compared to controls, patients had
greater activation in the left amygdala, accumbens, putamen, and ventral prefrontal cortex
when rating face hostility, and greater activation in the left amygdala and bilateral
accumbens when rating their own fear of the face. There were no between-group
behavioral or neural differences in the non-emotional conditions. Results implicate
deficient emotion-attention interactions in the pathophysiology of BD in youth, and
suggest that developmental psychobiology approaches to chronic mental illness have
broad applicability.
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INTRODUCTION

Recently, psychology and psychiatry have witnessed a major paradigm shift, in
that virtually all chronic adult mental illnesses are now viewed as end results of long-term
perturbations in the development of specific neural circuits. Two lines of research
support such a developmental perspective: family-based/longitudinal and neurobiological
studies. Family-based and longitudinal studies provide strong support for developmental
perspectives in a range of conditions, including behavior disorders, substance abuse,
mood disorders, and the psychoses (1-3). However, virtually all research on
developmental neurobiology focuses on schizophrenia, where the dominant theories
implicate a neural circuit connecting the dorsolateral prefrontal cortex to the striatum and
hippocampus (4, 5). Thus, an important next step in this developmentally focused
paradigm shift is the extension of the neurobiological research approach to other mental
illnesses.
For several reasons, bipolar disorder (BD) is an ideal illness in which to conduct
neurobiologically-oriented developmental research. The disorder is highly impairing,
causing marked disruption in social, academic, and family functioning. Major questions
persist concerning the boundaries of the condition in children, and neurobiological data
might ultimately speak to this controversy. Most importantly, research in adult patients
and animals implicates a circuit encompassing the amygdala, striatum, and associated
areas of the ventral prefrontal cortex (VPFC) in the pathophysiology of BD (6). This
circuit has been shown to have considerable developmental plasticity. In particular, the
identification of amygdala-based perturbations in children with BD would have profound
implications for developmental conceptualizations of chronic mental illness, since it
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would suggest that perturbations in neural development play a role in diverse mental
illnesses, with specific circuits implicated in specific conditions.
Research to date supports the value of developmental studies focusing specifically
on amygdala structure and function in BD. Structural magnetic resonance imaging
(MRI) studies in bipolar adults find either increased or unchanged amygdala volume
relative to controls (7-11), while studies in bipolar children consistently document
decreased amygdala volume in patients compared to controls (12-16). fMRI studies find
that adults with BD, relative to controls, have either amygdala hyperactivation (17) or
hypoactivation in response to facial stimuli (18). While the few fMRI studies in pediatric
BD have not revealed functional abnormalities in the amygdala (19, 20), these studies
have not employed paradigms ideally suited for examining amygdala function.
Here, we used an fMRI face processing task to study youth with BD and controls.
We link behavioral measures of emotion processing with function in a neural circuit
encompassing the amygdala, VPFC, and striatum, using a task that directs subjects’
attention toward or away from emotional aspects of faces rated neutral by a healthy,
normative sample. We chose this paradigm because children with BD have difficulty
categorizing facial emotions (21), and their attentional performance is more impaired in
emotional than in non-emotional contexts (22). These two deficits may be related:
children with BD may mislabel facial emotions because their affective response to a face
disrupts emotion categorization. We also chose this paradigm because it engages the
amygdala-striatal-VPFC circuit (23, 24), which has been implicated in the
pathophysiology of BD, and mediates facial expression processing and the direction of
attention toward or away from emotional stimuli (25-29). We used neutral faces in the
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task because individuals with mood disorders tend to misperceive such faces as negative
(30, 31). Moreover, the current study was able to document the on-line occurrence of
such cognitive misperceptions in BD during face viewing, allowing us to elucidate
amygdala-based correlates of this deficit.
Consistent with previous research (22), we expected to see behavioral and
neurophysiological deficits in BD youth only when they attended to emotional aspects of
the neutral face. Specifically, we hypothesized that during emotional, but not nonemotional tasks, children with BD, compared to controls, would have greater activation
in the amygdala, striatum, and VPFC, and would report more negative subjective ratings
and have slower reaction times.

MATERIALS AND METHODS
Inclusion/Exclusion Criteria
BD (N=22) and control (N=21) subjects were enrolled in an ongoing
neurocognitive and neuroimaging study at the National Institute of Mental Health
(NIMH). Subjects were recruited via advertisements to patient advocacy groups and
letters to practicing psychiatrists. The NIMH IRB approved the study. Parents and
children gave written informed consent/assent.
Inclusion criteria for the BD sample required that subjects ages 9-17 meet
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)(32) criteria
for BD, including a history of at least one hypomanic or manic episode meeting full
duration criteria—i.e. lasting > 4 days—during which the child exhibited abnormally
elevated and expansive mood and at least three other criterion “B” symptoms (33).
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Children with a history of irritability only, without elevated or expansive mood, and those
without distinct manic episodes were excluded; thus, this sample met criteria for the
narrow phenotype of pediatric BD (34). The Kiddie-Schedule for Affective DisordersPresent and Lifetime Version (K-SADS-PL) (35) was administered to parents and
children separately by clinicians with established reliability (i.e. kappa > 0.9). Comorbid
psychiatric diagnoses were based on symptoms present during euthymia. Control
subjects and a parent also completed the K-SADS to ensure that the subject had no
psychiatric history.
Exclusion criteria included I.Q. < 70, pervasive developmental disorder,
psychosis that interfered with study compliance, unstable medical illness, substance
abuse within two months of the initial evaluation, and for controls, psychiatric illness in a
first-degree relative.
To evaluate mood at the time of scanning, graduate level clinicians with
established inter-rater reliability administered to patients and their parents the Children’s
Depression Rating Scale (CDRS)(36), and the Young Mania Rating Scale (YMRS)(37)
within 24 hours of the scan. IQ was measured with the Wechsler Abbreviated Scale of
Intelligence (WASI)(38).

Behavioral Task
Participants viewed 32 adult faces (8 each of happy, angry, fearful, and neutral).
Grayscale face stimuli were selected from standardized sets constructed by Ekman and
Friesen (39), Gur (www.uphs.upenn.edu/bbl/pubs/downloads/nptasks.shtml), and
Tottenham and Nelson (www.macbrain.org/faces/index.htm). As previously noted, in this
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analysis we included only neutral face trials in order to maximize our ability to detect
between-group differences in emotion-attention interactions. However, subjects were
also shown emotional faces (i.e. happy, angry, fearful) to reduce boredom and habituation
from repeated exposure to similar stimuli (40, 41).
We used the frequently employed “rapid event related” paradigm of Friston (42)
and Zarahn & Slifstein (43). On each trial, using a 5-key button box (MRI Devices,
Waukesha, WI), subjects rated the displayed face on one of three 5-point scales: 1) the
threat-level of the face (“How hostile is the face?”); 2) their emotional response to the
face (“How afraid are you?”); or 3) a non-emotional facial feature (“How wide is the
nose?”). These rating tasks directed the subject’s attention to either emotional or nonemotional aspects of the face. Fixation trials were also included as control trials and to
facilitate data analysis. Each face or fixation cross was displayed for 4000 ms to allow
subjects to rate each face while viewing it, with minimal demands on working memory
(44). Each stimulus or fixation was followed by an inter-trial interval varying in duration
from 750-1250 ms. Visual stimuli were displayed on Avotec Silent Vision Glasses
(Stuart, FL). Practice sessions with novel stimuli ensured that participants understood the
tasks before scanning.
There were four blocks in the experiment: one for each of the three rating types,
and one for passive viewing. Rating instructions were presented for 3000 ms before each
block. Each block comprised 10 trials (eight of the 32 faces, 2 fixations). Blocks were
grouped into epochs, with each epoch consisting of four blocks, one for each task. These
four 40-trial epochs were integrated into one 160-trial run. Block and trial order were
randomized across participants.
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MRI Data Acquisition
Whole-brain blood oxygen level dependent (BOLD) fMRI data were acquired on
a General Electric Signa 3T scanner. Following sagittal localization and manual
shimming, functional T2* weighted images were acquired using an echo-planar singleshot gradient echo pulse sequence with a matrix size of 64 x 64, repetition time (TR) of
2000 ms, echo time (TE) of 40 ms, field of view of 240 mm and voxels of 3.75 x 3.75 x 5
mm. Images were acquired in 23 contiguous 5 mm axial slices per brain volume
positioned parallel to the AC-PC line. All functional data were gathered in a single 14
minute run for each subject. After EPI acquisition, a high resolution T1 weighted
anatomical image was acquired to aid with spatial normalization. A standardized
magnetization prepared gradient echo sequence (180 1 mm sagittal slices, FOV=256,
NEX=1, TR=11.4 ms, TE=4.4 ms, matrix=256x256, TI=300 ms, bandwidth=130
Hz/pixel, 22 kHz/256 pixels) was used.

Data Analysis
Behavioral Data
To evaluate potential between-group differences in behavioral performance, two 2
x 3 repeated measures ANOVAs were conducted. Dependent variables for the two
ANOVAs were rating scores (hostility, afraid, nose width) and reaction time (RT),
respectively. For both ANOVAs, group (BD vs. control) was the between-subject factor,
and rating type (hostility, afraid, nose width) was the within-subject factor. Statistical
corrections were implemented where assumptions of sphericity or homoscedasticity were
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violated. The Greenhouse-Geisser procedure was applied when appropriate. Post-hoc
comparisons employed the Tukey test.

fMRI Data
For each subject, reconstructed fMRI images were examined for excessive motion
using MedX software. Subjects who moved more than 1.5 mm in any plane were
discarded. Analyses were conducted with SPM software (SPM99, Wellcome Department
of Neurology, London U.K.) and Matlab 5.3 routines. Functional data were corrected for
slice timing, motion corrected, co-registered to the anatomical data, and spatially
normalized to a Montreal Neurological Institute (MNI) T1-weighted template image
supplied with SPM99. After preprocessing, fMRI images were visually inspected to
evaluate the quality of the normalization procedure.
At the individual subject level, event-related response amplitudes were estimated
using the General Linear Model (GLM) for each of the four event types: subjects rating
afraid, hostility, or nose width during neutral face viewing, and fixation. The waveform
used to model event-related response in the GLM was a rectangular pulse (4s duration)
convolved with the hemodynamic response function specified by SPM99. Contrast
images were generated for each subject using pairwise comparisons of the event-related
BOLD responses across event types. Since the goal of the current study was to examine
emotion-attention interactions, the contrasts of interest compared activation during an
emotional task (rating hostility or fear) vs. a non-emotional task (rating nose width or
viewing a fixation cross). Thus, the primary contrasts, all with neutral faces, were: afraid
rating vs. nose width rating (“afraid vs. nose”), afraid rating vs. fixation (“afraid vs.
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fixation”), hostile rating vs. nose width rating (“hostile vs. nose”), and hostile rating vs.
fixation (“hostile vs. fixation”).
Each contrast image was divided by the subject specific voxel time series means,
yielding values proportional to percentage fMRI signal change (45). Each contrast image
was then smoothed with an isotropic Gaussian kernel (FWHM =11.4) to decrease nonstationarity in the spatial autocorrelation structure introduced by the previous step.
For all group-level analyses, a random effects model was used to permit
population-level inferences (46). To test our a priori hypotheses, we used the Gaussian
random field threshold (p<.05) in selected regions of interest (ROIs) and applied the
small volume correction within each region. The ROIs were bilateral amygdala, VPFC,
and ventral striatum (i.e. accumbens, putamen, and caudate). Each was defined, using
standard anatomical criteria (47), on the canonical structural MRI images provided by
SPM 99 software and then applied to all normalized brains at the group level.
Coordinates are in Montreal Neurological Institute (MNI) space. Binary masks for each
ROI consisted of voxels in which all subjects showed a measurable BOLD response; thus
subjects’ data were not differentially affected by signal dropout in difficult-to-image
regions.
Although all faces were shown for 4 seconds, between-group differences in RT or
ratings may reflect between-group differences in the time spent attending to the face or
evaluating emotional aspects of the stimuli; these could affect the magnitude of the
BOLD signal (48). Thus, secondary analyses covaried for RT and ratings in instances
where neural activation differed significantly between patients and controls. Bivariate
correlational analyses were used to examine associations between the magnitude of the
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BOLD signal at the peak voxels within those ROIs that showed significant betweengroup differences, and ratings of hostility or fear.

RESULTS
Participant Demographics and Clinical Characteristics (Supporting Text: Table 1)
Patients (N = 22) and controls (N = 21) did not differ on age (BD=14.2 + 3.1
yrs; control= 4.5 + 2.5 yrs), sex (male: BD=45.5%; control=52.4%), or IQ (BD=109.3 +
11.6; control=114.3 + 11.4). Of the patients, 90.9% (N=20) met criteria for Bipolar I;
81.8% (N=18) had at least one additional diagnosis, and the mean number of comorbid
diagnoses was 1.4 + 1.1. At the time of scanning, 81.8% (N = 18) of patients were
medicated, with a mean of 2.5 + 1.8 medications per subject.
The patients’ mean CDRS score was 29.2 + 9.3, and the mean YMRS score was
9.0 + 6.1. 54.5 % (N=12) of the children with BD were euthymic at the time of scanning.
Of the ten non-euthymic patients, four were depressed (CDRS > 40, YMRS <12) and six
were hypomanic (YMRS > 12 but < 26, CDRS < 40).

Behavioral Data
Ratings
The repeated measures ANOVA showed a significant group x ratings interaction
[F(2,82)=6.08, p=.008)]. Post hoc analyses found that patients, compared to controls,
rated the neutral faces as significantly more hostile (BD=2.00 + 0.61; controls=1.56 +
0.39; t=2.80, p=.008) and themselves as significantly more afraid (BD= 2.02 + 0.88;
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control=1.39 + 0.38; t=3.02, p=.004) (Supporting Text: Table 2a). There were no
between-group differences on nose width ratings.

Reaction time
The repeated measures ANOVA of RT during ratings found a significant group x
ratings interaction [F(2,40)=11.36, p<.001)]. Post hoc analyses found that patients were
significantly slower than controls to rate the faces’ hostility (BD=2203.59 + 326.12 ms,
controls= 1754.90 + 276.08 ms; t=4.86, p<.001) (Supporting Text: Table 2b). There
were no significant between-group differences in RT on afraid or nose width ratings.

fMRI Data
Primary between-group contrasts
Afraid vs. nose width; afraid vs. fixation
We compared patients and controls on neural activation when viewing neutral
faces and rating “how afraid” vs. “nose width” (i.e., the “afraid vs. nose width” contrast).
Compared to controls, patients had significantly greater activation in the left amygdala
(t=4.05, p=.001) and bilateral accumbens (left: t=3.68, p=.003; right: t=2.58, p=.037)
(Figure 1; Supporting Text: Table 3). Similarly, on the afraid vs. fixation contrast,
patients had significantly greater activation than controls in the bilateral amygdala (left:
t=3.40, p=.008; right: t=3.03, p=.019), left accumbens (t=3.04, p=.018), and left putamen
(t=3.45, p=.016) (Supporting Text: Table 3).

Hostile vs. nose width; hostile vs. fixation
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Activation (to neutral faces?) during the hostility rating and the two nonemotional tasks was compared. In the hostile vs. nose width contrast, patients had
significantly greater activation than controls in the left amygdala (t=3.44, p=.006), left
accumbens (t=2.81, p=.025), left putamen (t=3.13, p=.026), and left VPFC (t=3.21,
p=.032) (Figure 2; Supporting Text: Table 3). Similarly, in the hostile vs. fixation
contrast, patients had significantly greater activation than controls in the bilateral
amygdala (left: t=3.22, p=.011; right: t=2.93, p=.021) and bilateral putamen (left: t=3.11,
p=.029; right: t=2.87, p=.049) (Supporting Text: Table 3).

Post hoc contrasts
Within-group contrasts on emotional tasks
To confirm that the between-group differences reflected limbic hyperactivation
during the emotional tasks in patients but not controls, we performed within-group
comparisons. In patients, the afraid vs. nose width contrast revealed significant
activation in the left amygdala (t=4.32, p=.001), left nucleus accumbens (t=2.76, p=.028),
and bilateral VPFC (left: t=3.87, p=.007; right: t=2.90, p=.05) (Supporting Text: Table
4). A similar analysis in controls revealed activation only in the right VPFC (t=3.64,
p=.01). In the hostile vs. nose width contrast, patients had activation in the bilateral
amygdala (left: t=4.09, p=.001; right: t=2.57, p=.04), left accumbens (t=2.81, p=.025),
left caudate (t=2.98, p=.031), and left putamen (t=2.98, p=.036) (Supporting Text: Table
4). The same contrast in controls revealed no activation.

Between-group contrasts on non-emotional tasks
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To ascertain if neural activation differed between the two groups on the nonemotional control tasks, we compared patients and controls on the nose width rating vs.
fixation contrast. There were no between-group differences on this contrast.

Associations with behavioral data
Covarying for reaction time and ratings
Because patients were significantly slower than controls to make hostility ratings,
we examined the hostile vs. nose width and hostile vs. fixation contrasts using RT as a
covariate. All between-group differences remained significant. Specifically, patients had
significantly greater activation than controls in the left amygdala (t=3.71, p=.003),
accumbens (t=2.54, p=.044), and putamen (t=2.86, p=.047) on the hostile vs. nose width
contrast, and in the left amygdala (t=2.47, p=.05) and putamen (t=2.80, p=.05) in the
hostile vs. fixation contrast.
Given that our patients rated neutral faces as significantly more hostile and fearprovoking than did controls, we re-examined the contrasts using ratings as a covariate.
All of the ROIs that showed significant between-group differences in the afraid vs. nose
width and afraid vs. fixation contrasts remained significant when controlling for ratings.
On the hostile vs. nose width contrast, the left amygdala (t=3.44, p=.006) and VPFC
(t=3.21, p=.032) remained significant when covaried for ratings, and on the hostile vs.
fixation contrast, the bilateral amygdala (left: t=3.22, p=.011; right: t=2.93, p=.021)
difference remained significant.

Correlation of neural activation with ratings
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Because patients rated the faces as more hostile and fear-producing than did
controls, for each group we examined correlations between ratings and activation at the
peak voxel of each ROI that had revealed significant between-group differences. In
controls, there were no significant correlations between ratings and activation; in the
patients, hostile ratings correlated with activation of the left amygdala on the hostile vs.
nose width rating (r=.51, p=.01). Between-group comparison of the correlation between
left amygdala activation and the hostile vs. nose width rating within each sample using a
Fisher r-to-z calculation found the correlation in the BD sample to be significantly greater
than that in controls (z=2.32, p=.02) (Supporting Text: Figure 3).

Relationships between mood, medication, comorbidity, and activation
Given the heterogeneity of our patients with regard to mood status during
scanning, comorbid diagnoses, and treatment, we conducted a series of ANOVAs and
bivariate correlational analyses to compare activation within subgroups of the patients at
the peak voxels in the ROIs. We found no differences in activation between euthymic
and non-euthymic patients, those with and without comorbid anxiety disorders, or those
with and without comorbid ADHD. Also, there were no significant correlations between
neural activation and CDRS or YMRS scores. Finally, we found no significant
correlations between activation and the number of medications patients were taking.
Moreover, examination of fMRI response in the four medication-free subjects revealed
similar response patterns in medicated and un-medicated subjects. Nevertheless, given
the small sample sizes in these post-hoc analyses, one must interpret them cautiously.
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DISCUSSION

An emerging paradigm views chronic mental illnesses as developmental
perturbations in specific neural circuits. Prior studies implicate a DLPFC-based circuit in
developmental models of schizophrenia and an amygdala-based circuit in adult BD
samples. Our results in pediatric BD are consistent with the latter work: we demonstrate
functional deficits in an amygdala-striatal-VPFC circuit (49), while demonstrating that
such hyperactivation occurs specifically when patients attend to the emotion that they
perceive on a face, or to their emotional response to a face, but not when they attend to a
non-emotional facial feature.
Taken together, prior studies in schizophrenia and the current study in pediatric
BD document the broad applicability of the developmental psychobiology approach.
Diverse forms of chronic psychopathologies that typically manifest in adulthood appear
to reflect the end result of developmental perturbations in psychobiology. Furthermore,
distinct conditions involve perturbations in distinct neural circuits. The hope is that the
identification of psychobiological abnormalities early in the course of an illness may
allow for more successful interventions before a chronic course is established.
Given that we were able to specify the context in which limbic dysfunction occurs
in BD, our results provide evidence, not only for the value of research based in
developmental systems neuroscience, but also for the importance of acquiring behavioral
measures while subjects are being scanned and for using paradigms that yield patientcontrol differences in behavior. Routinely acquiring behavioral measures in clinical
fMRI studies, as is done in cognitive neuroscience studies on control subjects, will
improve investigators’ ability to interpret neuroimaging data.
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We expected to find between-group differences in behavior because, in a previous
study (22), we found that children with BD demonstrate aberrant behavior and
neurophysiology in emotional, but not non-emotional, contexts. Clinical researchers have
debated the advantages and disadvantages of using fMRI paradigms that yield differences
in behavior between patients and controls (48, 50). We suggest that paradigms showing
such between-group differences in behavior may yield particularly informative
neuroimaging results because, to the extent that these differences are relevant to patients’
symptomatology, identifying group differences in neural activation while subjects
perform the task may help to elucidate the pathophysiology of the illness (48). Of course
it is important to ensure that such differences do not confound the interpretation of fMRI
data. Here, we used an event-related design and appropriate statistical corrections to
control for behavioral differences on a trial-by-trial basis.
We found that, when subjects’ attention was directed to emotional aspects of
neutral faces, the faces elicited more negative attributions in BD patients than in controls,
as well as more limbic activation. Moreover, we found that the magnitude of this
negative attribution predicted the degree of amygdala hyperactivation in patients, but not
in healthy subjects. Thus, children with BD may have a tendency to perceive neutral
stimuli more negatively than do healthy children. This behavioral deficit may result from
limbic hyperactivation and contribute to clinical manifestations of pediatric BD.
However, since this is an associational study, it is unclear if BD results from, or causes,
the differences we observed in subjective ratings, RT, and limbic hyperactivation.
Neural hyperactivation in patients, compared to controls, was most evident
bilaterally in the amygdala, and was also seen in the bilateral accumbens, putamen, and
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left VPFC during emotional tasks (ratings of hostility or fearfulness). In particular, our
data provide strong evidence implicating the left amygdala in dysfunctional face
processing in pediatric BD, since between-group comparisons, within-group analyses,
and correlations between BOLD signal and behavioral data all found an association
between increased left amygdala activity and negative perceptions of neutral faces in the
patients. Our finding of exaggerated amygdala response to faces in bipolar children is
consistent with prior work in bipolar adults (51, 52). Furthermore, studies in controls
indicate that fluctuating attentional task demands modulate amygdala activation while
subjects process emotional stimuli (23, 53). Our results indicate that amygdala
hyperactivation in pediatric BD may result from dysregulation of this emotion-attention
mechanism, since patients engage the amygdala more than do controls only when
attention is directed to the emotional components of a neutral stimulus.
There is now increasing evidence that children with BD have deficient social
skills (54) and difficulty interpreting facial expressions (21). Here, we found that children
with BD also misinterpret neutral facial expressions as being significantly more hostile
and fear-inducing than do controls. Competence in social interactions requires proficient
face processing and the over-identification of anger in neutral facial displays is associated
with affective aggression and irritability (55). Since the latter behaviors are common in
pediatric BD, further study of face processing in these patients may help elucidate the
causes of functional impairment and suggest potential targets for therapeutic
interventions.
A primary limitation of the current study is that, since most of our patients were
medicated, it is unclear the extent to which our results are associated with BD itself or,
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instead, reflect the patients’ use of medication. The literature addressing the impact of
medication on fMRI results in pediatric BD is limited, since 3 of 4 fMRI and 16 of 17
structural MRI studies in children with BD have included medicated patients (56-58). In
adults with BD, one study did find frontal hyperactivation to be associated with
medication; compared to unmedicated patients, medicated patients had increased
dorsolateral PFC and anterior cingulate activation during a Stroop task (59). In contrast,
two fMRI comparisons of medicated and unmedicated bipolar adults (60, 61), and one
unpublished study in children with BD (62) found more marked differences in activation
between unmedicated bipolar patients and controls than between medicated bipolar
patients and controls, suggesting that medication may lead to Type II, rather than Type I,
errors. In addition, previous work in adults with BD (51) or depression (63) indicates
that lithium, antipsychotics and antidepressants may normalize neural activation in
response to facial expressions. Due to ethical limitations of medication discontinuation,
it is very difficult to obtain data in a sizable sample of unmedicated children with BD.
Alternative designs may be needed to fully evaluate the role of neural circuitry
dysfunction vs. that of medication. For example, a longitudinal study of youth at risk for
BD may generate data in medication-free youth, document amygdala-based deficits
similar to those found here, and relate them to future clinical manifestations of BD.
Another limitation is the high rate of comorbidity in our patients, although this
rate is typical of that seen in other clinical samples of children with BD (64). When we
compared patients with and without comorbid anxiety or ADHD, we did not find
between-group differences in neural activation. However, the small sample sizes limit
the interpretation of these negative results. Future research could determine the extent to
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which patterns of neural activation in children with BD differ based on the presence of
comorbid conditions. Further, given that hyperactivation of the amygdala, along with an
attentional bias to emotional stimuli, has been demonstrated in other childhood mood
disorders (23, 65-67), it will be important to determine whether the current results are
specific to pediatric BD, as opposed to other childhood psychiatric illnesses. As
previously noted, we anticipate that different psychopathologies would be associated with
dysfunction in different neural circuits.
Finally, while half of our patients were euthymic, the other half presented in a
depressed or hypomanic state during testing. When we compared euthymic vs. noneuthymic patients, we did not find between-group differences in neural activation.
Again, caution should be used when interpreting these negative results due to the small
sample sizes. Replication of our current results with a larger sample size will help to
elucidate the impact of medication, comorbidity, and mood on the behavioral and
neurological responses to faces in children with BD.
In sum, our results demonstrate abnormal emotion-attention interactions in
pediatric BD that are associated with increased activation in the amygdala and ventral
striatum and negative attributions of neutral faces. These findings add to prior studies of
adults with BD. Taken together, the current and prior data support the view of serious,
chronic, adult mental disorders as the end result of developmental perturbations in
specific neural circuits.
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FIGURE LEGENDS

Figure 1: Greater neural activation in children with bipolar disorder (N=22) vs.
controls (N=21) when rating their fear of neutral faces
Figure displays voxels where patients exhibited greater activation than controls
on the afraid vs. nose width contrast for neutral faces. For the purpose of visual
presentation, the threshold in this figure is set at p<.01 uncorrected. Peak voxels are in
the left amygdala (x=-14, y=-2, z=-10), left accumbens (x=-10, y=4, z=-12), and right
accumbens (x=12, y=4, z=-10).

Figure 2:

Greater neural activation in children with bipolar disorder (N=22) vs.

controls (N=21) when rating the hostility of neutral faces
Figure displays voxels where patients exhibited greater activation than controls
on the hostility vs. nose width contrast for neutral faces. For the purpose of visual
presentation, the threshold in this figure is set at p<.01 uncorrected. Peak voxels are in
the left amygdala (x=-22, y=4, z=-18), left accumbens (x=-14, y=12, z=-10), left
putamen (x=-24, y=8, z=-10), and left VPFC (x=-32, y=20, z=-16).

Supporting Text, Figure 3: Correlation between peak left amygdala activation on the
hostile vs. nose width contrast and ratings of the hostility of neutral faces
Figure displays, in control and BD subjects viewing neutral faces, the
correlation between peak left amygdala activation (x=-22, y=4, z=-18) on the hostility
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vs. nose width contrast and hostility ratings. Correlation was significant in the BD
sample (r=.51, p=.014), but nonsignificant in controls (r=-.19, p=.40).
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